Clinical Trials Browser

Phase 2 × Neoplasm, Residual × Trastuzumab × Clear all

NCT01401959 2018-06-15

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Phase 2 Completed

127 enrolled 11 charts

Breast Neoplasms, Neoplasm, Residual